Drug firm Lupin Limited on Friday said that, "it has launched the Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (FDA) earlier", in filing to Bombay Stock Exchange.
"Lupin's Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc's Synthroid® Tablets. It is indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer", the company added.
"Levothyroxine Sodium Tablets, 25 meg, SO meg, 75 meg, 88 meg, 100 meg, 112 meg, 125 meg, 137 meg, 150 meg, 175 meg, 200 meg, and 300 meg had an annual sales of approximately USD 2.5 billions in the U.S (IQVIA MAT January 2019)", Lupin said.
The shares of Lupin were trading at Rs. 747.35 apiece, low at 5.20 points or 0.69 per cent at 13:05 hours on the BSE.